Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

Background This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formulated with either the AS01B or AS02A Adjuvant Systems. Methodology/Principal Findings After a preliminary safety evaluation of low dose AMA-1/AS01B (10 µg/0.5 mL) in 5 adults, 30 malaria-naïve adults were randomly allocated to receive full dose (50 µg/0.5 mL) of AMA-1/AS01B (n = 15) or AMA-1/AS02A (n = 15), followed by a malaria challenge. All vaccinations were administered intramuscularly on a 0-, 1-, 2-month schedule. All volunteers experienced transient injection site erythema, swelling and pain. Two weeks post-third vaccination, anti-AMA-1 Geometric Mean Antibody Concentrations (GMCs) with 95% Confidence Intervals (CIs) were high: low dose AMA-1/AS01B 196 µg/mL (103–371 µg/mL), full dose AMA-1/AS01B 279 µg/mL (210–369 µg/mL) and full dose AMA-1/AS02A 216 µg/mL (169–276 µg/mL) with no significant difference among the 3 groups. The three vaccine formulations elicited equivalent functional antibody responses, as measured by growth inhibition assay (GIA), against homologous but not against heterologous (FVO) parasites as well as demonstrable interferon-gamma (IFN-γ) responses. To assess efficacy, volunteers were challenged with P. falciparum-infected mosquitoes, and all became parasitemic, with no significant difference in the prepatent period by either light microscopy or quantitative polymerase chain reaction (qPCR). However, a small but significant reduction of parasitemia in the AMA-1/AS02A group was seen with a statistical model employing qPCR measurements. Significance All three vaccine formulations were found to be safe and highly immunogenic. These immune responses did not translate into significant vaccine efficacy in malaria-naïve adults employing a primary sporozoite challenge model, but encouragingly, estimation of parasite growth rates from qPCR data may suggest a partial biological effect of the vaccine. Further evaluation of the immunogenicity and efficacy of the AMA-1/AS02A formulation is ongoing in a malaria-experienced pediatric population in Mali. Trial Registration www.clinicaltrials.gov NCT00385047

[1]  A. Thomas,et al.  Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02 , 2008, PloS one.

[2]  M. Demoitié,et al.  Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2008, Vaccine.

[3]  V. A. Stewart,et al.  Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. , 2008, Vaccine.

[4]  V. A. Stewart,et al.  Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial , 2008, PloS one.

[5]  M. Tanner,et al.  A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers , 2007, PloS one.

[6]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[7]  A. Batchelor,et al.  Structural basis of antigenic escape of a malaria vaccine candidate , 2007, Proceedings of the National Academy of Sciences.

[8]  Marie-Claude Dubois,et al.  A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. , 2007, Vaccine.

[9]  V. A. Stewart,et al.  Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2007, Vaccine.

[10]  M. Fay,et al.  Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria , 2007, PLoS clinical trials.

[11]  David L. Smith,et al.  Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali , 2007, PLoS medicine.

[12]  V. A. Stewart,et al.  Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. , 2006, Vaccine.

[13]  D. Webster,et al.  A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge , 2006, Infection and Immunity.

[14]  K. Sperber,et al.  Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. , 2006, The Mount Sinai journal of medicine, New York.

[15]  E. Bergmann-Leitner,et al.  Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. , 2006, The American journal of tropical medicine and hygiene.

[16]  Joe D. Cohen,et al.  Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. , 2006, Vaccine.

[17]  F. Spertini,et al.  Academic Editor: Brian Greenwood, University of London, United Kingdom , 2005 .

[18]  D. Webster,et al.  Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria1 , 2005, The Journal of Immunology.

[19]  D. Webster,et al.  Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. , 2005, The American journal of tropical medicine and hygiene.

[20]  Hong Zhou,et al.  Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria , 2005, Infection and Immunity.

[21]  V. A. Stewart,et al.  Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). , 2005, The American journal of tropical medicine and hygiene.

[22]  V. A. Stewart,et al.  Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. , 2005, Vaccine.

[23]  D. Conway,et al.  Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.

[24]  Joe D. Cohen,et al.  Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. , 2004, Vaccine.

[25]  S. D. de Vlas,et al.  Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. , 2004, The American journal of tropical medicine and hygiene.

[26]  Markus S. Mueller,et al.  A Role for Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium falciparum Sporozoites* , 2004, Journal of Biological Chemistry.

[27]  A. Hill,et al.  Malaria vaccine developments , 2004, The Lancet.

[28]  A. Thomas,et al.  Apical Membrane Antigen 1, a Major Malaria Vaccine Candidate, Mediates the Close Attachment of Invasive Merozoites to Host Red Blood Cells , 2004, Infection and Immunity.

[29]  W. Ripley Ballou,et al.  Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1 , 2003, The Journal of Immunology.

[30]  B. Keegan,et al.  Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.

[31]  S. Ralph,et al.  Independent Translocation of Two Micronemal Proteins in Developing Plasmodium falciparum Merozoites , 2002, Infection and Immunity.

[32]  J. K. Moch,et al.  Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the Plasmodium falciparum Apical Membrane Antigen 1 Expressed in Escherichia coli , 2002, Infection and Immunity.

[33]  E. Linders,et al.  Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. , 2001, Molecular and biochemical parasitology.

[34]  S. Howell,et al.  Proteolytic Processing and Primary Structure ofPlasmodium falciparum Apical Membrane Antigen-1* , 2001, The Journal of Biological Chemistry.

[35]  B. Nahlen,et al.  Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. , 2001, The American journal of tropical medicine and hygiene.

[36]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[37]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[38]  Q. Cheng,et al.  Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. , 2000, Vaccine.

[39]  B. Nahlen,et al.  Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria , 1996, Infection and immunity.

[40]  I. Schneider,et al.  T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. , 1995, Journal of immunology.

[41]  A. Waters,et al.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen , 1988, Parasite immunology.

[42]  Milburn Cl,et al.  The Walter Reed Army Institute of Research. , 1961 .

[43]  C. Dye,et al.  World Malaria Report, 2008. , 2008 .

[44]  M. Fried,et al.  Malaria in the pregnant woman. , 2005, Current topics in microbiology and immunology.

[45]  R. Anders,et al.  Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. , 1998, Vaccine.

[46]  S. Hoffman,et al.  Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. , 1986, The American journal of tropical medicine and hygiene.